Community-based cognitive remediation program for schizophrenia and schizoaffective disorder
Integrative Neuro-social Cognitive Strategy Programme for Instilling REcovery (INSPIRE): a Community-Based Cognitive Remediation Trial
NA · Singapore Institute of Technology · NCT06286202
This study tests a community program that helps adults with schizophrenia and schizoaffective disorder improve their thinking skills through exercises and group support to see if it makes their daily lives better.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 160 (estimated) |
| Ages | 21 Years to 60 Years |
| Sex | All |
| Sponsor | Singapore Institute of Technology (other) |
| Locations | 5 sites (Singapore and 4 other locations) |
| Trial ID | NCT06286202 on ClinicalTrials.gov |
What this trial studies
This program aims to improve cognitive skills in adults with schizophrenia and schizoaffective disorders through a community-based cognitive remediation approach. Participants will engage in a structured intervention that includes computer-assisted exercises and group sessions facilitated by therapists. The study will also explore how motivation and social interaction influence cognitive improvements and functional abilities. The focus is on addressing cognitive impairments that hinder community integration and quality of life.
Who should consider this trial
Good fit: Ideal candidates are adults diagnosed with schizophrenia or schizoaffective disorder who have completed at least ten years of formal education and can converse in English.
Not a fit: Patients with neurological diseases, those unable to understand English, or those with very low functioning may not benefit from this program.
Why it matters
Potential benefit: If successful, this program could enhance cognitive functioning and improve the quality of life for patients with severe mental illnesses.
How similar studies have performed: Previous studies have shown positive outcomes with cognitive remediation approaches, suggesting potential for success in this community-based setting.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * A diagnosis of schizophrenia or schizoaffective disorder according to Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-V). * Completed at least ten years of formal education with English as the main instructional language. Participants need to be able to converse in English and understand English instructions, as the cognitive remediation program will be conducted in English. Exclusion Criteria: * Known neurological diseases and epilepsy, which affects gains from cognitive remediation. * Unable to speak and understand English. * Hospitalized within the past one month. * Global Assessment of Functioning score of 30 or below, as participants who are too low functioning are unable to benefit from a strategy learning approach.
Where this trial is running
Singapore and 4 other locations
- Anglican Care Center-Bukit Batok — Singapore, Singapore (RECRUITING)
- Anglican Care Center-Hougang — Singapore, Singapore (RECRUITING)
- Anglican Care Center-Pasir Ris — Singapore, Singapore (NOT_YET_RECRUITING)
- Anglican Care Center-Simei — Singapore, Singapore (RECRUITING)
- Anglican Care Center-Yishun — Singapore, Singapore (NOT_YET_RECRUITING)
Study contacts
- Principal investigator: Bhing-Leet Tan, PhD — Bhing-Leet Tan
- Study coordinator: Bhing-Leet Tan, PhD
- Email: bhingleet.tan@singaporetech.edu.sg
- Phone: +6598422783
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Schizophrenia, Schizoaffective Disorder, cognitive remediation, Neuropsychological and Educational Approach to Remediation, Multicontext Treatment Approach, metamotivation, psychiatric rehabilitation, schizophrenia